Gael B. Morrow, PhD

Postdoctoral Research Fellow
University of Oxford

Dr Gael B Morrow, PhD, University of Oxford

My main research interest lies in the dysregulation of fibrinolysis during inherited and acquired bleeding disorders. My current work focuses on two different types of fibrinogen replacement administered to trauma patients. Fibrinogen is the key pro-coagulant factor required for stable clot formation. Patients recruited to the Fibrinogen Early in Severe Trauma StudY (FEISTY) were given one of two treatments: cryoprecipitate or fibrinogen concentrate. My research investigates the differences in clot structure and strength between the two fibrinogens, and how this correlates with clinical outcome.

Presentation(s):

• OC 11.1 - Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and strength; results from a sub-study of the FEISTY trial

  Sunday, July 10, 2022
  10:45 AM – 11:00 AM

• PB0187 - FIX binding to collagen IV generates thrombin via the intrinsic tenase

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• PB0605 - COVID-19 disease is associated with a hypofibrinolytic state driven by elevated plasminogen activator inhibitor-1 and its cofactor vitronectin

  Monday, July 11, 2022
  6:30 PM – 7:30 PM